Personalized ovarian cancer vaccines set for human trials

It vaccine to treat patients with ovarian cancer, according to a new study. Researchers from the University of Connecticut say the vaccine stems from a new technique that identifies protein mutations in cancer cells, and the method is already set to enter human trials.

Read more

Priority Targets for Immunotherapy in Epithelial Ovarian Cancer Idendified

Newswise — BUFFALO, N.Y. — Researchers at Roswell Park Cancer Institute (RPCI) have found that the expression pattern of a unique class of tumor-associated antigens, known as the MAGE cancer-testis antigens (CTAs), correlates with clinical outcome in epithelial ovarian cancer. Based on their findings, the researchers have identified priority targets for ovarian cancer immunotherapy. Read more

Personalized ovarian cancer vaccine shows promise in trial

Delegates at a conference in the US this week are hearing about early results of a trial of a new personalized ovarian cancer vaccine that offers new hope for the large number of patients who relapse after treatment. Read more